The DOI matches its Crossref record; 35 of the 35 references it cites were found in a registry or an index.
5-HT2C Receptor Agonists: Pharmacological Characteristics and Therapeutic Potential
Abstract
In vitro, (S)-2-(chloro-5-fluoro-indol-1-yl)-1-methylethylamine 1:1 C4H4O4 and (S)-2-(4,4,7-trimethyl-1,4-dihydro-indeno[1, 2-b]pyrrol-1-yl)-1-methylethylamine 1:1 C4H4O4 exhibited high-affinity binding to the serotonin2C (5HT2C) receptors and stimulated turnover of inositol 1,4,5-triphosphate. Affinity to several of the other 5-HT receptor subtypes and to numerous nonserotonergic receptors was much lower. In rats, both compounds elicited behavioral signs of 5-HT2C receptor agonism but not 5-HT2A receptor agonism. Hypomotility induced in rats by high doses of these compounds was reversed by the 5-HT2C receptor antagonist N-(2-naphthyl)-N'-(3-pyridyl)-urea 1:1 HCI. In addition, these compounds were active in tests used to demonstrate anticompulsive effects: reducing schedule-induced polydipsia in rats (prevented by the 5-HT2C/2B receptor antagonist N-(1-methyl-5'-indolyl)-(3-pyridyl)urea 1:1 HCl, reversing increased scratching induced with 8-hydroxy-dipropylaminotetralin 1:1 HCl in squirrel monkeys (no tolerance developed), decreasing responding in the marble-burying task in mice, and decreasing excessive eating of palatable food in rats. In contrast to these compounds, fluoxetine was much less potent, and in some tasks less efficacious, in reducing excessive behavior in these models. These two 5-HT2C receptor agonists do not show anxiogenic effects in the plus-maze in rats. (S)-2-(4,4,7-trimethyl-1,4-dihydro-indeno[1, 2-b]pyrrol-1-yl)-1-methylethylamine 1:1 C4H4O4 reduced the olfactory bulbectomy-induced passive avoidance impairment in rats, a result that indicates antidepressant potential. Similarly, in the differential-reinforcement-of-low rate 72-s operant schedule task in rats, (S)-2-(chloro-5-fluoro-indol-1-yl)-1-methylethylamine 1:1 C4H4O4 increased (and (S)-2-(4,4,7-trimethyl-1,4-dihydro-indeno[1, 2-b]pyrrol-1-yl)-1-methylethylamine 1:1 C4H4O4 showed a tendency to increase) total reinforcements received, which is suggestive of antidepressant activity. The electroencephalography defined sleep-waking pattern in rats produced by these two 5-HT2C agonists, as well as fluoxetine, included increased quiet-waking and decreased rapid-eye-movement sleep, which is characteristic of antidepressant drugs. These results suggest that 5-HT2C receptor agonism is associated with therapeutic potential in obsessive compulsive disorder and depression.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
LIGAND: A versatile computerized approach for characterization of ligand-binding systems
Munson, P. J., & Rodbard, D. (1980) · Analytical Biochemistry · doi:10.1016/0003-2697(80)90515-1 · Cited by 8,429
Eating disorder and epilepsy in mice lacking 5-HT2C serotonin receptors
Tecott, L. H., Sun, L. M., Akana, S. F., Strack, A. M., Lowenstein, D. H., Dallman, M. F., & Julius, D. (1995) · Nature · doi:10.1038/374542a0 · Cited by 1,274
Pompeiano, M., Palacios, J. M., & Mengod, G. (1994) · Molecular Brain Research · doi:10.1016/0169-328x(94)90223-2 · Cited by 881
5-HT2 receptor subtypes: A family re-united?
Baxter, G., Kennett, G., Blackburn, T., & Blaney, F. (1995) · Trends in Pharmacological Sciences · doi:10.1016/s0165-6147(00)88991-9 · Cited by 345
Goa, K. L., & Ward, A. (1986) · Drugs · doi:10.2165/00003495-198632020-00002 · Cited by 332
m-Chlorophenylpiperazine as a probe of serotonin function
Kahn, R. S., & Wetzler, S. (1991) · Biological Psychiatry · doi:10.1016/0006-3223(91)90184-n · Cited by 292
Abramowski, D., Rigo, M., Duc, D., Hoyer, D., & Staufenbiel, M. (1995) · Neuropharmacology · doi:10.1016/0028-3908(95)00138-7 · Cited by 243
Serotonin receptors: Subtypes, functional responses and therapeutic relevance
Saxena, P. R. (1995) · Pharmacology & Therapeutics · doi:10.1016/0163-7258(94)00005-n · Cited by 225
In vivo properties of SB 200646A, a 5‐HT2C/2Breceptor antagonist
Kennett, G. A., Wood, M. D., Glen, A., Grewal, S., Forbes, I., Gadre, A., & Blackburn, T. P. (1994) · British Journal of Pharmacology · doi:10.1111/j.1476-5381.1994.tb14808.x · Cited by 181
Sleep and treatment prediction in endogenous depression
(1981) · American Journal of Psychiatry · doi:10.1176/ajp.138.4.429 · Cited by 171
Activation of Meningeal 5‐HT2B Receptors: An Early Step in the Generation of Migraine Headache?
Schmuck, K., Ullmer, C., Kalkman, H. O., Probst, A., & Lübbert, H. (1996) · European Journal of Neuroscience · doi:10.1111/j.1460-9568.1996.tb01583.x · Cited by 154
Involvement of 5-HT1C-receptors in drug-induced penile erections in rats
Berendsen, H. H. G., Jenck, F., & Broekkamp, C. L. E. (1990) · Psychopharmacology · doi:10.1007/bf02253718 · Cited by 149
Self-citationWoods-Kettelberger, A. T., Smith, C., Szewczak, M. R., Dunn, R. W., Cornfeldt, M. L., & Corbett, R. (1993) · Psychopharmacology · doi:10.1007/bf02244910 · Cited by 137
New mouse 5‐HT2‐like receptor Expression in brain, heart and intestine
Loric, S., Launay, J., Colas, J., & Maroteaux, L. (1992) · FEBS Letters · doi:10.1016/0014-5793(92)80936-b · Cited by 130
Moreau, J., Bös, M., Jenck, F., Martin, J. R., Mortas, P., & Wichmann, J. (1996) · European Neuropsychopharmacology · doi:10.1016/0924-977x(96)00015-6 · Cited by 128
Self-citationEffects of the 5‐HT2B receptor agonist, BW 723C86, on three rat models of anxiety
Kennett, G. A., Bright, F., Trail, B. K., Baxter, G. S., & Blackburn, T. P. (1996) · British Journal of Pharmacology · doi:10.1111/j.1476-5381.1996.tb15304.x · Cited by 122
Milne, R. J., & Heel, R. C. (1991) · Drugs · doi:10.2165/00003495-199141040-00006 · Cited by 118
Moser, P. C., Tricklebank, M. D., Middlemiss, D. N., Mir, A. K., Hibert, M., & Fozard, J. R. (1990) · British Journal of Pharmacology · doi:10.1111/j.1476-5381.1990.tb14706.x · Cited by 115
O’Donnell, J. M., & Seiden, L. S. (1983) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(25)33434-8 · Cited by 107
Sleight, A. J., Stam, N. J., Mutel, V., & Vanderheyden, P. (1996) · Biochemical Pharmacology · doi:10.1016/0006-2952(95)02122-1 · Cited by 92
Self-citationBerendsen, H. H. G. (1995) · Pharmacology & Therapeutics · doi:10.1016/0163-7258(94)00075-e · Cited by 82
Self-citationCurrent issues in the pharmacologic management of obsessive compulsive disorder.
Rasmussen, S. A., Eisen, J. L., & Pato, M. T. (1993) · PubMed · Cited by 74
Broekkamp, C. L. E., Garrigou, D., & Lloyd, K. G. (1980) · Pharmacology Biochemistry and Behavior · doi:10.1016/0091-3057(80)90006-4 · Cited by 72
Self-citationJenck, F., Moreau, J., Berendsen, H. H. G., Boes, M., Broekkamp, C. L. E., Martin, J. R., Wichmann, J., & Delft, A. M. L. V. (1998) · European Neuropsychopharmacology · doi:10.1016/s0924-977x(97)00055-2 · Cited by 68
Self-citationMoreau, J., Jenck, F., Martin, J. R., Perrin, S., & Haefely, W. E. (1993) · Psychopharmacology · doi:10.1007/bf02246963 · Cited by 66
Self-citationBrain 5-HT1C receptors and antidepressants
Jenck, F., Moreau, J.-L., Mutel, V., & Martin, J. R. (1994) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/0278-5846(94)90013-2 · Cited by 62
Self-citationBehavioral profile of the 5HT1A receptor antagonist (S)-UH-301 in rodents and monkeys
Moreau, J., Griebel, G., Jenck, F., Martin, J. R., Widmer, U., & Haefely, W. E. (1992) · Brain Research Bulletin · doi:10.1016/0361-9230(92)90163-r · Cited by 58
Self-citationOpiate-Androgen Interactions in Drug-Induced Yawning and Penile Erections in the Rat
Berendsen, H. H. G., & Gower, A. J. (2008) · Neuroendocrinology · doi:10.1159/000124438 · Cited by 53
Self-citationBerendsen, H. H. G., & Broekkamp, C. L. E. (1994) · European Journal of Pharmacology · doi:10.1016/0014-2999(94)90760-9 · Cited by 51
Self-citationFluoxetine suppresses palatability-induced ingestion
Leander, J. D. (1987) · Psychopharmacology · doi:10.1007/bf00518178 · Cited by 46
Ruigt, G. S. F., Proosdij, J. N. V., & Delft, A. M. L. V. (1989) · Electroencephalography and Clinical Neurophysiology · doi:10.1016/0013-4694(89)90019-9 · Cited by 45
Self-citationMaswood, S., Andrade, M., Caldarola-Pastuszka, M., & Uphouse, L. L. (1996) · Neuropharmacology · doi:10.1016/0028-3908(95)00195-6 · Cited by 34
Ruigt, G. S. F., Proosdij, J. N. V., & Wezenbeek, L. (1989) · Electroencephalography and Clinical Neurophysiology · doi:10.1016/0013-4694(89)90020-5 · Cited by 27
Self-citationden Boer, J. A., & Westenberg, H. G. M. (1995) · Human Psychopharmacology Clinical and Experimental · doi:10.1002/hup.470100906 · Cited by 18
Advances in the Treatment of Anorexia Nervosa and Bulimia Nervosa
Kennedy, S. H., & Goldbloom, D. S. (1994) · CNS Drugs · doi:10.2165/00023210-199401030-00005 · Cited by 3
Cited by
Molecular, pharmacological and functional diversity of 5-HT receptors
Hoyer, D., Hannon, J. P., & Martin, G. R. (2002) · Pharmacology Biochemistry and Behavior · doi:10.1016/s0091-3057(01)00746-8 · Cited by 1,865
Aripiprazole, A Novel Atypical Antipsychotic Drug with a Unique and Robust Pharmacology
Shapiro, D. A., Renock, S., Arrington, E., Chiodo, L. A., Liu, L.-X., Sibley, D. R., Roth, B. L., & Mailman, R. (2003) · Neuropsychopharmacology · doi:10.1038/sj.npp.1300203 · Cited by 968
The neurobiology and control of anxious states
Millan, M. J. (2003) · Progress in Neurobiology · doi:10.1016/s0301-0082(03)00087-x · Cited by 965
Serotonin control of sleep-wake behavior
Monti, J. M. (2011) · Sleep Medicine Reviews · doi:10.1016/j.smrv.2010.11.003 · Cited by 614
Fidler, M. C., Sanchez, M., Raether, B., Weissman, N. J., Smith, S. R., Shanahan, W. R., & Anderson, C. M. (2011) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2011-1256 · Cited by 561
Metadata
- Authors
- Martin, J. R., Bös, M., Jenck, F., Moreau, J.-L., Mutel, V., Sleight, A. J., Wichmann, J., Andrews, J. S., Berendsen, H. H. G., Broekkamp, C. L. E., Ruigt, G. S. F., Köhler, C., & van Delft, A. M. L.
- Venue
- The Journal of Pharmacology and Experimental Therapeutics
- Publisher
- Elsevier BV
- Published
- 1998-08
- Volume
- 286
- Issue
- 2
- Pages
- 913-924
- ISSN
- 0022-3565 (ISSN-L)
- OpenAlex
- W2134923721
- Cited by
- 334
- References
- 35
- FWCI
- 4.96
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.